Frontiers in Drug Design and Discovery

Volume 7


Atta-ur-Rahman, Mohammad Iqbal Choudhary

DOI: 10.2174/97816810816561160701
eISBN: 978-1-68108-165-6, 2016
ISBN: 978-1-68108-166-3
ISSN: 1574-0889 (Print)
ISSN: 2212-1064 (Online)

Indexed in: Scopus, EMBASE, EBSCO, Ulrich's Periodicals Directory.

Frontiers in Drug Design and Discovery is an eBook series devoted to publishing...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Cardiotoxicity of Cancer Chemotherapy–Recent Developments

- Pp. 36-83 (48)

Rui Adao, Carolina Maia-Rocha, Diana Santos-Ribeiro, Pedro Mendes- Ferreira, Adelino F. Leite-Moreira and Carmen Bras-Silva


The extensive use of chemotherapy in clinical practice has led to considerable controversy due to their potential adverse cardiovascular effects in surviving cancer patients. Among the effects of chemotherapeutic agents on the cardiovascular system, the most frequent and serious is heart failure with ventricular systolic dysfunction. Other harmful effects include hypertension, thromboembolic disease, pericardial disease, arrhythmias and myocardial ischemia. Cancer therapyinduced cardiomyopathy was almost exclusively associated with the use of cumulative doses of anthracyclines. However, new therapeutic agents, such as the monoclonal antibody trastuzumab, induce transient reversible myocyte dysfunction. Recent research to limit cardiotoxicity has focused on early monitoring and risk stratification to identify patients that are ‘at risk’ for cardiotoxicity, using biochemical markers and the prophylactic use of novel cardioprotective agents. This chapter reviews the clinical course, pathogenesis, cardiac monitoring and new concepts in diagnosing and preventing chemotherapy cardiotoxicity.

Purchase Chapter  Book Details


Webmaster Contact: Copyright © 2019 Bentham Science